Oral topotecan: bioavailability and effect of food co-administration
Open Access
- 11 June 1999
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 80 (9) , 1380-1386
- https://doi.org/10.1038/sj.bjc.6690532
Abstract
The aims of the study were twofold: (1) to evaluate the effect of food on the relative oral bioavailability of topotecan gelatin capsules in patients with solid tumours, and (2) to determine the absolute bioavailability of oral topotecan with reference to the intravenous (i.v.) formulation. The study had a randomized two-period cross-over design. On day 1 of the first treatment course patients were administered 2.3 mg m–2 day–1 of oral topotecan with or without a high-fat breakfast. They crossed over to receive the alternate regimen on day 2. In the second course (3 weeks later) fasted patients received topotecan orally (2.3 mg m–2 day–1) or i.v. (1.5 mg m–3 day). They crossed over to receive the alternate regimen on day 2. On days 3–5 of both treatment courses patients received oral topotecan. Plasma pharmacokinetics were performed on days 1 and 2 of the first and second course using a high-performance liquid chromatographic assay. Eighteen patients were enrolled in the study. The ratio of the area under the curve to infinity during fasted and high-fat treatment was 0.93 ± 0.23 (90% confidence interval (CI) 0.83–1.03). Maximal plasma concentrations of topotecan were similar after ingestion of the capsules with (10.6 ± 4.4 ng ml–1) or without food (9.2 ± 4.1 ng ml–1) (P = 0.130). The time needed to reach maximal plasma levels was significantly prolonged after food intake (median 3.1 h, range 2.8–6.1) compared to fasted conditions (2.0 h, range 1.1–8.1) (P = 0.013). The absolute bioavailability of topotecan averaged 42 ± 13% (90% CI 37– 47%). The apparent terminal half-life was significantly longer after administration of oral topotecan (3.9 ± 1.0 h) than after i.v. administration (2.7 ± 0.4 h) (P < 0.001). Topotecan demonstrates suitable bioavailability for oral treatment. Co-administration of the topotecan gelatin capsules with a high-fat breakfast leads to a small decrease in absorption rate but does not affect the extent of absorption.Keywords
This publication has 16 references indexed in Scilit:
- 927 A phase I and bioavailability study of oral topotecanEuropean Journal Of Cancer, 1995
- 116 The pharmacokinetics of topotecan (T) and its carboxylate (C) form following separate intravenous administration to the dogEuropean Journal Of Cancer, 1995
- Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumorsCancer Chemotherapy and Pharmacology, 1995
- High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solutionJournal of Pharmaceutical and Biomedical Analysis, 1990
- Review of methods and criteria for the evaluation of bioequivalence studiesEuropean Journal of Clinical Pharmacology, 1990
- Comprehensive Criteria for Assessing Therapy-Induced ToxicityCancer Investigation, 1989
- Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activityJournal of Medicinal Chemistry, 1989
- IDENTIFICATION OF MAMMALIAN DNA TOPOISOMERASE-I AS AN INTRACELLULAR TARGET OF THE ANTICANCER DRUG CAMPTOTHECIN1988